Nemaura Medical (Nasdaq:NMRD) announced today that it received Saudi Food and Drug Authority (SFDA) approval for its sugarBEAT sensor. The company develops daily, non-invasive, disposable, wearable glucose sensors. It also offers digital diabetes management tools and earlier this year added CGM-guided insulin dose titration to its offerings. Nemaura’s sugarBEAT, a CE-marked device, offers non-invasive, flexible continuous […]
Nemaura Medical
Nemaura Medical secures $6.5M in funding
Nemaura Medical (Nasdaq:NMRD) announced that it brought in $6.5 million in non-dilutive funding through a clean debt facility. The Loughborough, England-based company said its debt facility features no warrants or convertible elements. It comes from the company’s existing lender. Nemaura Medical did not list an intended use for the added funds. The company develops daily, […]
Nemaura Medical to offer CGM-guided insulin dose titration care model
Nemaura Medical (Nasdaq:NMRD) announced today that it now includes insulin under its DuoPack commercial license agreement. Loughborough, UK-based Nemaura Medical entered into a commercial agreement in September 2021 with MySugarWatch DuoPack Limited (MSWDL). Under the agreement, Nemaura’s non-invasive, wearable skin patch sensors paired with prescription-only medicines for type 2 diabetes. This created the MySugarWatch-branded “DuoPack.” […]
Nemaura Medical garners U.S.-based purchase order for glucose sensors
Nemaura Medical (Nasdaq:NMRD) announced that it received a purchase order for 5,000 proBEAT glucose sensor subscriptions. HealthFleet, a U.S.-based telehealth provider, made the purchase order. It consists of 75,000 proBEAT glucose sensors over an initial five-month period. Nemaura values the deal at $500,000 in revenue, while HealthFleet possesses the option to increase volumes based on […]
Nemaura Medical announces $11.5m public offering
Nemaura Medical (NSDQ:NMRD) announced that it intends to offer shares of its common stock and warrants in a “best efforts” public offering. The Loughborough, England-based wearable diagnostic device developer for people with diabetes said in a news release that the offering includes an aggregate of up to nearly 1.6 million shares of common stock and warrants […]
Nemaura adds activity data to ProBeat app
Nemaura Medical (NSDQ:NMRD) announced today that it commissioned the integration of data to its ProBeat app set for U.S. launch this year. Data from third-party wearable devices can now be integrated into the ProBeat system, which is a wearable, non-invasive glucose monitor designed to gather big data centered around factors that affect blood glucose levels, according […]
Nemaura pulls in $5m loan
Wearable diagnostic device developer Nemaura Medical (NSDQ:NMRD) announced today that it secured a $5 million non-convertible loan. The Loughborough, England–based company currently commercializing the SugarBeat continuous glucose monitor (CGM) received the 24-month loan, which does not include warrants or other equity securities, from Chicago Venture Partners, according to a news release. “This loan strengthens our financial […]
Nemaura Medical repurposes its CGM to spot coronavirus fevers
Nemaura Medical (NSDQ:NMRD) announced today that it is planning to immediately repurpose its SugarBeat continuous glucose monitor (CGM) as a continuous temperature monitor (CTM) to help diagnose fevers in potential cases of COVID-19. The Loughborough, England-based company said in a news release that its inbuilt temperature sensor is capable of continuously tracking body temperature through the […]
Nemaura Medical enters non-binding agreements for its SugarBeat platform
Nemaura Medical (NSDQ:NMRD) announced today that it entered into multiple verbal non-binding agreements for its SugarBeat continuous glucose monitor as it seeks to secure regional and global partnerships. The Loughborough, U.K.–based company expects the agreements to lead to discussions over licensing and collaboration, but can’t guarantee that deals will be struck as planned, or at all, […]
Nemaura Medical launches SugarBeat app
Nemaura Medical (NSDQ:NMRD) announced that it launched its SugarBeat app for continuous glucose monitoring on Android devices in the Play Store as it prepares to debut a subscription-based service. The Loughborough, England–based company’s SugarBeat is a non-invasive and flexible CGM designed to pair with BeatDiabetes, the company’s planned health subscription service for people with Type 2 […]
Nemaura bids for de novo clearance from FDA for SugarBEAT glucose monitor
Nemaura Medical (NSDQ:NMRD) this week said it submitted a De Novo medical device applications to the FDA for its SugarBEAT non-invasive glucose monitor. The Loughborough, England-based company recently successfully completed clinical studies and two summative human factors usability studies needed to support De Novo submission. Get the full story on our sister site, Drug Delivery Business.